1384424-80-9 Usage
Description
1-(7-Methoxyquinolin-4-yl)-3-[6-(trifluoromethyl)pyridin-2-yl]urea, also known as A-1070722, is a potent inhibitor of glycogen synthase kinase 3β (GSK-3β) with an IC50 value of less than 100 nM. It is a neuroprotective agent that targets the conserved catalytic domain of GSK-3, which is involved in various biological processes such as apoptosis, synaptic plasticity, axon formation, and neurogenesis. 1-(7-Methoxyquinolin-4-yl)-3-[6-(trifluoromethyl)pyridin-2-yl]urea has potential therapeutic applications in treating neurodegenerative and psychiatric disorders.
Uses
Used in Pharmaceutical Industry:
1-(7-Methoxyquinolin-4-yl)-3-[6-(trifluoromethyl)pyridin-2-yl]urea is used as a neuroprotective agent for the treatment of neurodegenerative and psychiatric disorders. Its ability to inhibit GSK-3β makes it a promising candidate for modulating the signaling pathways involved in these conditions, potentially leading to improved therapeutic outcomes.
Used in Research Applications:
In the field of research, 1-(7-Methoxyquinolin-4-yl)-3-[6-(trifluoromethyl)pyridin-2-yl]urea serves as a valuable tool for studying the role of GSK-3β in various cellular processes. By inhibiting this enzyme, researchers can gain insights into the molecular mechanisms underlying its regulation and the potential therapeutic benefits of targeting GSK-3β in different disease contexts.
Check Digit Verification of cas no
The CAS Registry Mumber 1384424-80-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,4,4,2 and 4 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1384424-80:
(9*1)+(8*3)+(7*8)+(6*4)+(5*4)+(4*2)+(3*4)+(2*8)+(1*0)=169
169 % 10 = 9
So 1384424-80-9 is a valid CAS Registry Number.
1384424-80-9Relevant articles and documents
HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
-
Page/Page column 34, (2012/07/14)
The present invention relates to novel heterocyclic compounds of formula I wherein the variables are as defined in the claims or the description, which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3β, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3β activity using the compounds.
